Prathamesh Pathak
YOU?
Author Swipe
View article: Clinical Outcomes in Patients With Muscle-Invasive Urothelial Carcinoma Treated With Nivolumab
Clinical Outcomes in Patients With Muscle-Invasive Urothelial Carcinoma Treated With Nivolumab Open
Importance Nivolumab is a standard-of-care adjuvant therapy for patients with muscle-invasive urothelial carcinoma (MIUC) at high risk for recurrence after radical resection. However, a better understanding of its use and clinical effectiv…
View article: Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma
Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma Open
Potential CD19 antigen loss following CD19-directed therapy has raised concerns over sequential use of these therapies. Tafasitamab, a CD19-targeting immunotherapy, combined with lenalidomide, is approved for relapsed or refractory diffuse…
View article: Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis
Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis Open
Aim: In rheumatoid arthritis (RA), seropositivity for both anticitrullinated protein antibody (ACPA) and rheumatoid factor (RF) is associated with disease severity and therapeutic response. Biologic (b) disease-modifying antirheumatic drug…
View article: Real-World Effectiveness of Tafasitamab (Tafa) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States
Real-World Effectiveness of Tafasitamab (Tafa) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States Open
Introduction: Tafa is a CD19-targeting immunotherapy indicated in combination with lenalidomide (len) for the treatment of R/R DLBCL in adult patients (pts) ineligible for autologous stem cell transplantation. To date, few studies have exa…
View article: REAL-WORLD USE OF TAFASITAMAB FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE UNITED STATES BY PRIMARY REFRACTORY STATUS
REAL-WORLD USE OF TAFASITAMAB FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE UNITED STATES BY PRIMARY REFRACTORY STATUS Open
Objectives: Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma with variable prognoses. Patients with primary refractory DLBCL tend to have poor outcomes with second-line therapy and beyond. Tafasitamab, a CD19-targeting immun…
View article: REAL-WORLD USE OF TAFASITAMAB FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE UNITED STATES BY AGE GROUP (> 70 YEARS AND 70 YEARS)
REAL-WORLD USE OF TAFASITAMAB FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE UNITED STATES BY AGE GROUP (> 70 YEARS AND 70 YEARS) Open
Objectives: Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of lymphoma that occurs more frequently in older adults. Tafasitamab, a CD19-targeting immunotherapy, combined with lenalidomide, was approved by the US Food and Drug …
View article: REAL-WORLD SEQUENTIAL USE OF CD19-DIRECTED THERAPIES FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: TAFASITAMAB PRECEDING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY
REAL-WORLD SEQUENTIAL USE OF CD19-DIRECTED THERAPIES FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: TAFASITAMAB PRECEDING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY Open
Objectives: Potential CD19 antigen loss following CD19-directed therapy has raised concerns over sequential use of these therapies, and real-world data are limited. Tafasitamab, a CD19-targeting immunotherapy, combined with lenalidomide, i…
View article: Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai
Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai Open
Objectives To characterize the pattern of approved anti-vascular endothelial growth factor (VEGF) treatments among patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) in the United Arab Emirat…
View article: Profiling Clinical Characteristics and Treatment Patterns Among Non-Valvular Atrial Fibrillation Patients: A Real-World Analysis in Dubai, United Arab Emirates
Profiling Clinical Characteristics and Treatment Patterns Among Non-Valvular Atrial Fibrillation Patients: A Real-World Analysis in Dubai, United Arab Emirates Open
Background: There is a dearth of real-world evidence regarding patient characteristics, Oral Anti-Coagulant (OAC) treatment, and International Normalized Ratio (INR) patterns in Dubai, United Arab Emirates (UAE). Methods: This was a retros…
View article: Wound closure under the influence of DC field
Wound closure under the influence of DC field Open
A possible mechanism of wound closure by direct current (DC) field is studied. DC stimulation reduces the surface area of a wound more rapidly in comparison to the other stimulations (Reger et al. 1999). It orients new collagen formation e…